Studying gut bacteria and scarring in Crohn's disease
Studies gut bacteria and scar tissue in adults with Crohn's disease.
Key facts
- Who runs it
- IRCCS San Raffaele
- Where
- Milan, ItalySee the site
- Trial code
- Registry title
- The Microbial Impact on Intestinal Fibrosis and the Associated Immune Microenvironment in Crohn's Disease
- Status
- Not yet recruiting
- People taking part
- 20 people, planned
- Started
- Apr 2025
- Expected to end
- Jan 2027
- Type of study
- Observational, 2 groups
- Treatments tested
- Collection of surgical specimen
- Collection of stool sample
- Record updated
- 14 February 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with Crohn's disease and adults without inflammatory bowel disease. Samples of gut tissue and stool are collected to study gut bacteria and scar tissue.
- Age
- 18 to 69 years (at least 18 and under 70)
- Sex
- All sexes
- Disease stage
- People with Crohn's disease need an established diagnosis. They are grouped as B1 (more inflammatory, non-stricturing), B2 (stricturing, non-penetrating) or B3 (stricturing and penetrating). Others have another condition such as diverticulitis, without inflammatory bowel disease.
- Earlier treatment
- People without inflammatory bowel disease cannot have had anti-inflammatory or immunosuppressive treatment for IBD-related diseases.
Main reasons for not taking part
- Under 18 or over 70 years
- Pregnant or breastfeeding
- Cannot sign the informed consent on their own
- Crohn's disease patients who do not meet the stage criteria
- Non-IBD patients on anti-inflammatory or immunosuppressive treatment for IBD-related diseases
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Adult patients ≥18 and <70 years
- Patients able to autonomously sign the informed consent
- Non pregnant or breastfeeding patients
- For CD patients: CD patients with established diagnosis and additionally classified according to 3 stages: B1 (more inflammatory, non-stricturing), B2 (stricturing, non-penetrating) and B3 (stricturing and penetrating). Patients will be stratified on the basis of CT, MRI or ultrasound analysis (stratification already known before surgery)
- For non-IBD patients: patients with other pathologies but not affected by IBD according to the previously reported clinical and endoscopic evaluation criteria (ex. diverticulitis)
Who cannot take part
- For non-IBD patients: Patients undergoing anti-inflammatory and/or immunosuppressive treatments for IBD-related diseases
- Patients <18 years or > 70 years
- Pregnant or breastfeeding patients
- For CD Patients: Subjects with CD who do not meet evaluation criteria described above
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 69 years old?
Where in Italy
- IRCCS San RaffaeleMilan, ItalyContact: Federica Ungaro, PhD.Not yet recruiting
About the trial
What the trial wants to find out
The goal of this study is to find out if there is a direct connection between an imbalance of gut bacteria and the development of scar tissue in the gut by identifying important bacterial proteins found in scarred gut tissue. Our aim is to identify which types of cells and biological processes are affected by these bacterial proteins in people with Crohn's Disease. We will also study how these bacterial proteins cause changes in 3D models of gut fibrosis.
The 2 groups in the trial
- CD Patients
CD patients with established diagnosis and additionally classified according to 3 stages: B1 (more inflammatory, non-stricturing), B2 (stricturing, non-penetrating) and B3 (stricturing and penetrating). Patients will be stratified on the basis of CT, MRI or ultrasound analysis (stratification already known before surgery)
Treatment: Collection of surgical specimen and Collection of stool sample
- Non-IBD Patients
Patients with other pathologies but not affected by IBD according to the previously reported clinical and endoscopic evaluation criteria (ex. diverticulitis)
Treatment: Collection of surgical specimen and Collection of stool sample
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Unveiling the Microbial Impact on Intestinal Fibrosis and the Associated Immune Microenvironment: New Insights for the Pathogenesis and Treatment of Crohn's Disease-associated Complications
- Plain-language title
- Studying gut bacteria and scarring in Crohn's diseaseGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Fit questions
- Built from NCT06720961, who can take part
- Record updated
- 14 February 2025